Identification of a smooth muscle cell (SMC) specific smooth muscle heavy chain (SM-MHC) promoter/enhancer
AssigneeSetagon, Inc.
InventorsGary K. Owens, Cort Madsen
Life of this patent
Estimating the term…
Loading patent…
AssigneeSetagon, Inc.
InventorsGary K. Owens, Cort Madsen
Estimating the term…
The present invention generally relates to promoters, enhancers and other regulatory elements of smooth muscle cells (“SMC”). The invention also generally relates to the use of these promoters, enhancers and other regulatory elements of SMC to create animal models to study SMC physiology and pathophysiology. The invention further relates to a smooth muscle myosin heavy chain (SM-MHC) promoter/enhancer element which is capable of conferring SMC-specific gene expression in vivo. The invention also relates to methods for the targeted knockout, or over-expression, of genes of interest within smooth muscle cells. The invention further relates to methods of conferring smooth muscle cell specific gene expression in vivo.
A method of expressing a polynucleotide in a smooth muscle cell in vitro comprising, introducing into said smooth muscle cell said polynucleotide in operative association with a SM-MHC promoter/enhancer, wherein the SM-MHC promoter enhancer is selected from the group consisting of
An isolated SM-MHC promoter/enhancer comprising a portion of a rat myosin heavy chain gene wherein said promoter/enhancer is capable of conferring SMC specific expression in vivo and wherein the portion consists of a sequence from about −4.2 kb to about +11.7 kb with respect to the transcription start site of said rat myosin heavy chain gene.
An isolated SM-MHC promoter/enhancer comprising a portion of a rat myosin heavy chain gene wherein said promoter/enhancer is capable of conferring SMC specific expression in vivo and wherein the portion consists of a sequence from about +1 kb to about +11.7 kb with respect to the transcription start site of said rat myosin heavy chain gene.
An isolated polynucleotide comprising a human SM-MHC promoter/enhancer in operable association with a heterologous polynucleotide, wherein the promoter/enhancer comprises sufficient sequence from the first intron of the human SM MHC gene to confer SMC-specific expression in vivo.
Dependencies are inferred from the claim text.